Apimeds Pharmaceuticals US Inc.

About Apimeds Pharmaceuticals US Inc.

Apimeds Pharmaceutical US, Inc. aims to transform human insight into breakthrough therapies by integrating actual intelligence with artificial intelligence. Their mission is to improve lives through the identification and development of therapies rooted in deep scientific insight, guided by a commitment to patients, physicians, and partners.

Products & Services

Apitox:A novel, non-narcotic therapy derived from purified honey bee venom, studied for the treatment of inflammation and pain, including in patients with osteoarthritis.

Specialties

Actual Intelligence (ai²™) Clinical Asset Identification Regulatory and IP Navigation Real-World Experience Evaluation Patient and Physician-Centric Decision Making

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: PIPE T: - FT: PIPE	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2025-12-10 FD: 2025-12-10	-
2	RT: Initial Public Offering T: - FT: Initial Public Offering	A: 13500000 MR: - FA: $13.5 million FAN: 13500000	D: 2025-05-12 FD: 2025-05-12	1 investors

PIPE Latest

2025-12-10

$100.0M

Initial Public Offering 2025-05-12

$13.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Erik Emerson

CEO

Recent News